COVID-19 burden and benefit of vaccination in individuals at increased risk funds education for healthcare professionals to strengthen understanding of COVID-19 risks, complications, and vaccination benefits.
Funder: Pfizer Inc.
Due Dates: January 14, 2027 (Submission deadline, 11:59 p.m. EST)
Funding Amounts: Up to $300,000 for multi-country or regional programs; up to $100,000 for local programs; maximum 1 year
Summary: Supports independent medical education on COVID-19 burden, complications, and vaccination benefits for people at increased risk of severe disease.
Key Information: Projects must be outside the United States; clinical research is not supported.
Pfizer’s competitive independent medical education initiative supports education for primary care physicians, pharmacists, specialists, nurses, midwives, other vaccinators, and vaccination advocates. It focuses on COVID-19 burden and acute and long-term consequences among people at increased risk of severe disease, particularly those with underlying comorbidities. Priorities include cardiovascular outcomes, new-onset or worsening diabetes and cardiovascular disease, updated vaccines’ protection against severe disease and longer-term complications, and COVID-19/influenza vaccine coadministration.
Projects may develop tools, resources, and training that strengthen professionals’ understanding of risk, confidence in addressing vaccine hesitancy, and communication with patients and communities. Eligible formats include online courses, webinars, congress symposia, videos, podcasts, infographics, animations, peer forums, and continuing education activities. Accredited activities are encouraged where appropriate. Content must be independently developed, evidence-based, balanced, and non-promotional.